BioCentury | Jan 31, 2020
Clinical News

AI strengthens grip on low hanging fruit with Exscientia, Dainippon Sumitomo trial start

Exscientia and Dainippon Sumitomo’s trial start for a compound accelerated through preclinical development via AI suggests the technology is starting to deliver on its first promise to drug developers: speeding up the chemistry they already...
BioCentury | Jan 4, 2020
Finance

All’s well that ends well

Biotech companies across all market cap tiers posted big gains in the fourth quarter of 2019, with median changes ranging from 7-18%. 4Q19 growth was enough to erase prior quarter losses, putting all tiers in...
BioCentury | May 30, 2017
Clinical News

FDA issues CRL for Sunovion’s COPD therapy

The Sunovion Pharmaceuticals Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said FDA issued a complete response letter for SUN-101 as a long-term maintenance treatment for airflow obstruction in patients with chronic obstructive pulmonary...
BioCentury | Jun 29, 2015
Company News

Dainippon Sumitomo, Takeda deal

The partners will terminate a 2011 deal granting Takeda exclusive rights to develop and commercialize Latuda lurasidone for schizophrenia and bipolar disorder in the EU, Switzerland, Norway, Turkey and Russia. The partners said the termination...
BioCentury | Dec 8, 2014
Company News

SanBio, Dainippon Sumitomo deal

Sumitomo exercised an option to co-develop and exclusively market SB623 in the U.S. and Canada. SanBio will receive $6 million up front and is eligible to receive up to $74 million in development milestones and...
BioCentury | Nov 3, 2014
Company News

GlaxoSmithKline, Dainippon Sumitomo deal

GlaxoSmithKline and Sumitomo terminated their 2012 co-promotion deal for antidepressant Paxil paroxetine CR in Japan, effective at year end. GSK will be solely responsible for providing information on Paxil CR , a once-daily Geomatrix formulation of...
BioCentury | Jun 23, 2014
Clinical News

Obeticholic acid regulatory update

FDA granted Fast Track designation to Intercept’s obeticholic acid to treat primary biliary cirrhosis (PBC). By 1H15, Intercept plans to submit an NDA to FDA and an MAA to EMA for the oral farnesoid X...
BioCentury | Jun 16, 2014
Clinical News

Vatiquinone regulatory update

Edison said FDA granted EPI-743 Orphan Drug designation to treat Leigh syndrome. The compound is in a U.S. Phase IIb trial and a Japanese Phase IIb/III trial for the indication, for which it already has...
BioCentury | Jun 12, 2014
Cover Story

Nav-i-gating antibodies for pain

Nav1.7 entered the limelight in the last decade as a pain target that could provide wide-ranging analgesia, but it has been difficult to target selectively over other voltage-gated sodium channels. Now, a team at the...
BioCentury | Jun 2, 2014
Clinical News

BBI608: Phase III discontinued

Dainippon discontinued the double-blind, placebo-controlled, international Phase III CO.23 trial evaluating twice-daily 480 mg BBI608 plus best supportive care (BSC) to treat colorectal cancer after a futility analysis based on DCR of the first 97...
Items per page:
1 - 10 of 418
BioCentury | Jan 31, 2020
Clinical News

AI strengthens grip on low hanging fruit with Exscientia, Dainippon Sumitomo trial start

Exscientia and Dainippon Sumitomo’s trial start for a compound accelerated through preclinical development via AI suggests the technology is starting to deliver on its first promise to drug developers: speeding up the chemistry they already...
BioCentury | Jan 4, 2020
Finance

All’s well that ends well

Biotech companies across all market cap tiers posted big gains in the fourth quarter of 2019, with median changes ranging from 7-18%. 4Q19 growth was enough to erase prior quarter losses, putting all tiers in...
BioCentury | May 30, 2017
Clinical News

FDA issues CRL for Sunovion’s COPD therapy

The Sunovion Pharmaceuticals Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said FDA issued a complete response letter for SUN-101 as a long-term maintenance treatment for airflow obstruction in patients with chronic obstructive pulmonary...
BioCentury | Jun 29, 2015
Company News

Dainippon Sumitomo, Takeda deal

The partners will terminate a 2011 deal granting Takeda exclusive rights to develop and commercialize Latuda lurasidone for schizophrenia and bipolar disorder in the EU, Switzerland, Norway, Turkey and Russia. The partners said the termination...
BioCentury | Dec 8, 2014
Company News

SanBio, Dainippon Sumitomo deal

Sumitomo exercised an option to co-develop and exclusively market SB623 in the U.S. and Canada. SanBio will receive $6 million up front and is eligible to receive up to $74 million in development milestones and...
BioCentury | Nov 3, 2014
Company News

GlaxoSmithKline, Dainippon Sumitomo deal

GlaxoSmithKline and Sumitomo terminated their 2012 co-promotion deal for antidepressant Paxil paroxetine CR in Japan, effective at year end. GSK will be solely responsible for providing information on Paxil CR , a once-daily Geomatrix formulation of...
BioCentury | Jun 23, 2014
Clinical News

Obeticholic acid regulatory update

FDA granted Fast Track designation to Intercept’s obeticholic acid to treat primary biliary cirrhosis (PBC). By 1H15, Intercept plans to submit an NDA to FDA and an MAA to EMA for the oral farnesoid X...
BioCentury | Jun 16, 2014
Clinical News

Vatiquinone regulatory update

Edison said FDA granted EPI-743 Orphan Drug designation to treat Leigh syndrome. The compound is in a U.S. Phase IIb trial and a Japanese Phase IIb/III trial for the indication, for which it already has...
BioCentury | Jun 12, 2014
Cover Story

Nav-i-gating antibodies for pain

Nav1.7 entered the limelight in the last decade as a pain target that could provide wide-ranging analgesia, but it has been difficult to target selectively over other voltage-gated sodium channels. Now, a team at the...
BioCentury | Jun 2, 2014
Clinical News

BBI608: Phase III discontinued

Dainippon discontinued the double-blind, placebo-controlled, international Phase III CO.23 trial evaluating twice-daily 480 mg BBI608 plus best supportive care (BSC) to treat colorectal cancer after a futility analysis based on DCR of the first 97...
Items per page:
1 - 10 of 418